The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

26 Mar 2009 15:47

RNS Number : 5628P
Amphion Innovations PLC
26 March 2009
 



Amphion Innovations plc

Directors Dealings

London and New York, 26 March 2009 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that Chief Executive Officer, Richard Morgan and President and Chief Financial Officer, Robert Bertoldi, who are also both Board members, have received New Ordinary Shares in lieu of cash compensation. Richard Morgan received 632,209 Ordinary Shares, bringing his total holdings of the Company to 23,426,266 representing 17.85 per cent of the Company's enlarged issued ordinary share capital. Robert Bertoldi received  75,865 Ordinary Shares bringing his total holdings of the Company to 6,436,431 representing 4.90 per cent of the Company's enlarged issued Ordinary Share capital.

In addition to the 708,074 Ordinary Shares issued to Richard Morgan and Robert Bertoldi, 166,903 Ordinary Shares were also issued to six employees of the Company as part of their incentive compensation. Admission of the 874,977 new Ordinary Shares, ranking pari passu, is expected on 2 April 2009. Following this allotment the total issued share capital of the Company will increase to 131,253,834 Ordinary Shares.

In addition, the Company has to date granted options to employees and Directors under the Share Option Scheme in respect of 7,875,000 Ordinary Shares. The Company is now proposing to grant options in respect of a further 1,925,000 Ordinary Shares at an issue price of 10.75 pence per Ordinary Share to certain employees and Directors which shall be exercisable from 24 March 2010 under the terms of the Share Option Scheme. This will include options in respect of 500,000 Ordinary Shares granted to Richard Morgan and 350,000 Ordinary Shares granted to Robert Bertoldi

Richard Morgan also purchased 150,000 Ordinary Shares on 25 March 2009. Of this, 113,640 Ordinary shares in the Company were purchased at a price of 10 pence per share and 36,360 Ordinary Shares at 11 pence per share in the Company Accordingly, Richard Morgan is now beneficially interested in 23,576,266 Ordinary Shares representing 17.97% of the Company's issued Ordinary Share capital. 

For further information please contact

Amphion Innovations plcCharlie Morgan, Director of Communications +1 212 210 6224

Cardew Group Tim Robertson/ Jamie Milton/ Matthew Law +44 020 7930 0777

Charles Stanley Securities - Nominated AdviserMark Taylor / Freddy Crossley +44 20 7149 6000

About Amphion Innovations plc Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEQLFLKXBZBBE
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.